Eli Lilly (LLY -1.2%) receives a blow in its attempts to overcome its patent expirations, saying...


Eli Lilly (LLY -1.2%) receives a blow in its attempts to overcome its patent expirations, saying its pomaglumetad methionil treatment for an acute exacerbation of schizophrenia missed the primary endpoint in a study. The company will await the results of two more trials before deciding its next steps.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs